ScholarLens Back to search
2009•University of Southern Denmark Research Portal (University of Southern Denmark)Requires access

Bevacizumab in combination with cetuximab and irinotecan (BCI) after failure of cetuximab and irinotecan (CI) in patients with metastatic colorectal cancer (mCRC)

Kristin Skougaard, Dorte Lisbet Nielsen, Per Pfeiffer, Trine Lembrecht Jørgensen, Jon Kroll Bjerregaard, Benny Vittrup Jensen

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Irinotecan, Cetuximab, Bevacizumab, Colorectal cancer, Medicine, Oncology, Internal medicine, Cancer

Back to paper searchBrowse research topicsOriginal source
Bevacizumab in combination with cetuximab and irinotecan (BCI) after failure of cetuximab and irinotecan (CI) in patients with metastatic colorectal cancer (mCRC) — Research Paper | ScholarLens